ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 10, 2015, Pages 17140-17150

  Qiu, Xiaoxin ^a   Hong, Yuan ^a   Yang, Darong ^b   Xia, Man ^a,e   Zhu, Haizhen ^a,b   Li, Qinglong ^c   Xie, Hailong ^d   Wu, Qunfeng ^e   Liu, Chen ^e   Zuo, Chaohui ^a,e  

^a Central South University   (China)

^b HUNAN UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d UNIVERSITY OF SOUTH CHINA   (China)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

HBV; Hepatocellular carcinoma; HLCZ01; Interferon alpha; ISG15; Prognostic biomarker

Indexed keywords

ALPHA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HORSERADISH PEROXIDASE; INTERFERON STIMULATED GENE 15; TRANSCRIPTION FACTOR; UBIQUITIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL STRESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSESSMENT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VIRUS STRAIN; WESTERN BLOTTING;

EID: 84949648231     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal A, Brany F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistitics. CA Cancer J Clin 2011; 61: 69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. In J Cancer 2010; 127: 2893-2917.
3. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C, Ng KK, Ching Chan S. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg 2011; 253: 745-758.
4. Qu LS, Jin F, Huang XW, Shen XZ. Interferon-αtherapy after Curative resection prevents early recurrence and improves survival in patients with hepatitics B virus-related hepatocellular carcinoma. J Surg Oncol 2010; 102: 796-801.
5. Fina RS. Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer 2012; 1: 247-256.
6. Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma review. Liver Cancer 2012; 1: 144-158.
7. Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, Kanzler S, Schulze-Bergkamen H, Galle PR. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independenity of p53. Cancer Res 2009; 69: 855-862.
8. Lamm D, Brausi M, O’Donnell MA, Witjes JA. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer. Urol Oncol 2014; 32: 35, e21-30.
9. Laurence A, Pesu M, Silvennoinen O, O’Shea J. JAK Kinases in Health and Disease: An Update. Open Rheumatol J 2012; 6: 232-244.
10. Yanai H, Negishi H, Taniguchi T. The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology 2012; 1: 1376-1386.
11. Sadier AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559-568.
12. Sridharan H, Zhao C, Krug RM. Species specificity of the NS1 protein of influenza B virus: NS1 binds only human and non-human primate ubiquitin-like ISG15 proteins. J Biol Chem 2010; 285: 7852-7856.
13. Wang W, Zhang M, Xiao ZZ, Sun L. Cynoglossus semilaevis ISG15: a secreted cytokine-like protein that stimulates antiviral immune response in a LRGG motif-dependent manner. PLoS One 2012; 7: e44884.
14. Giannakopoulos NV, Luo JK, Papov V, Zou W, Lenschow DJ, Jacobs BS, Borden EC, Li J, Virgin HW, Zhang DE. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun 2005; 336: 496-506.
15. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 2006; 94: 1456-1471.
16. Wood LM, Pan ZK, Seavey MM, Muthukumaran G, Paterson Y. The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy. Cancer Immunol Immunother 2012; 61: 689-700.
17. Hadjivasiliou A. ISG15 implicated in cytoskeleton disruption and promotion of breast cancer. Expert Rev Proteomics 2012; 9: 7.
18. Ina S, Hirono S, Noda T, Yamaue H. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance. Pancreas 2010; 39: 473-485.
19. Vincent-Chong VK, Ismail SM, Rahman ZA, Sharifah NA, Anwar A, Pradeep PJ, Ramanathan A, Karen-Ng LP, Kallarakkal TG, Mustafa WM, Abraham MT, Tay KK, Zain RB. Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11. Oral Dis 2012; 18: 469-476.
20. Cajee UF, Hull R, Ntwasa M. Modification by ubiquitin-like proteins: significance in apoptosis and autophagy pathways. Int J Mol Sci 2012; 13: 11804-11831.
21. Yang D, Zuo C, Wang X, Meng X, Xue B, Liu N, Yu R, Qin Y, Gao Y, Wang Q, Hu J, Wang L, Zhou Z, Liu B, Tan D, Guan Y, Zhu H. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. Proc Natl Acad Sci U S A 2014; 111: E1264-1273.
22. Li C, Wang J, Zhang H, Zhu M, Chen F, Hu Y, Liu H, Zhu H. Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget 2014; 5: 8429-8441.
23. Maheshwari A, Kantsevoy S, Jagannath S, Thuluvath PJ. Endoscopic ultrasound and fine-needle aspiration for the diagnosis of hepatocellular carcinoma. Clin Liver Dis 2010; 14: 325-332.
24. Pitha-Rowe IF, Pitha PM. Viral defense, carcinogenesis and ISG15: novel roles for an old ISG. Cytokine Growth Factor Rev 2007; 18: 409-417.
25. Laljee RP, Muddaiah S, Salagundi B, Cariappa PM, Indra AS, Sanjay V, Ramanathan A. Interferon stimulated gene-ISG15 is a potential diagnostic biomarker in oral squamous cell carcinomas. Asian Pac J Cancer Prev 2013; 14: 1147-1150.
26. Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A, Hartmann A, Dimmler A, Beckmann MW, Knüchel R, Fasching PA, Dahl E. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res 2008; 10: R58.
27. Darb-Esfahani S, Sinn BV, Rudl M, Sehouli J, Braicu I, Dietel M, Denkert C. Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic impact and link to NF-κB pathway. Int J Gynecol Pathol 2014; 33: 16-22.
28. Chairatvit K, Wongnoppavich A, Choonate S. Up-regulation of interferon-stimulated gene15 and its conjugates by tumor necrosis factor-α via type I interferon-dependent and -independent pathways. Mol Cell Biochem 2012; 368: 195-201.
29. Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, Liu Y, Dacic S, Siegfried JM, Dahlberg SE, Schiller JH, Belinsky SA. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene 2012; 31: 4107-4116.
30. Wan XX, Chen HC, Khan MA, Xu AH, Yang FL, Zhang YY, Zhang DZ. ISG15 inhibits IFN-α-resistant liver cancer cell growth. Biomed Res Int 2013; 2013: 570909.
31. Sgorbissa A, Brancolini C. IFNs, ISGylation and cancer: Cui prodest? Cytokine Growth Factor Rev 2012; 23: 307-314.